Sugita Yasuo, Tokunaga Osamu, Nakashima Akihiko, Shigemori Minoru
Department of Pathology and Biodefense, Saga Medical School, Saga, Japan.
Pathol Int. 2004 Sep;54(9):659-66. doi: 10.1111/j.1440-1827.2004.01677.x.
SHP-1 is an important negative regulator involved in signaling through receptors for cytokine/growth factors, and differential patterns of SHP-1 expression in several types of B-cell lymphomas closely resemble the patterns seen in their normal B cell counterparts. In an effort to elucidate the origin of primary central nervous system lymphomas (PCNSL), the present study assessed 32 cases of PCNSL. Tumors were subclassified according to WHO classification and were evaluated by immunohistochemistry for expression of antigens associated with germinal center (GC) (CD10, Bcl-6) and non-GC stages (SHP-1, CD138). Twenty-nine cases showed diffuse large-cell centroblastic morphology, whereas three cases showed diffuse large-cell immunoblastic morphology. The immunophenotypes of PCNSL were as follows: SHP-1+/Bcl-6-/CD10-/CD138- (12 of 32 cases); SHP-1+/Bcl-6+/CD10-/CD138- (15 of 32 cases); SHP-1+/Bcl-6+/CD10+/CD138- (two of 32 cases); SHP-1+/Bcl-6-/CD10+/CD138- (one of 32 cases); and SHP-1-/Bcl-6-/CD10-/CD138- (two of 32 cases). These results indicate that PCNSL might be distinct lymphomas that originate from a late germinal center to an early postgerminal center.
SHP-1是一种重要的负调节因子,参与细胞因子/生长因子受体介导的信号传导,并且在几种类型的B细胞淋巴瘤中SHP-1的表达差异模式与正常B细胞对应物中的模式非常相似。为了阐明原发性中枢神经系统淋巴瘤(PCNSL)的起源,本研究评估了32例PCNSL。肿瘤根据WHO分类进行亚分类,并通过免疫组织化学评估与生发中心(GC)相关抗原(CD10、Bcl-6)和非GC阶段抗原(SHP-1、CD138)的表达。29例表现为弥漫性大细胞中心母细胞形态,而3例表现为弥漫性大细胞免疫母细胞形态。PCNSL的免疫表型如下:SHP-1+/Bcl-6-/CD10-/CD138-(32例中的12例);SHP-1+/Bcl-6+/CD10-/CD138-(32例中的15例);SHP-1+/Bcl-6+/CD10+/CD138-(32例中的2例);SHP-1+/Bcl-6-/CD10+/CD138-(32例中的1例);以及SHP-1-/Bcl-6-/CD10-/CD138-(32例中的2例)。这些结果表明,PCNSL可能是起源于生发中心晚期至生发中心后早期的独特淋巴瘤。